Sugi Predict

Sugi Predict / Targets / PAK2

PAK2

Serine/threonine-protein kinase PAK 2 · Q13177 · PAK2 on Sugi Atlas →

5,049 patent compounds predicted against PAK2, 3,388 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4037995 SCHEMBL4037995 0.48 8/20
SCHEMBL13554009 SCHEMBL13554009 0.53 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1681117) 0.52 7/20
SCHEMBL13553784 SCHEMBL13553784 0.57 6/20
SCHEMBL13553777 SCHEMBL13553777 0.57 6/20
SCHEMBL13553780 SCHEMBL13553780 0.56 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1681161) 0.55 6/20
SCHEMBL13553685 SCHEMBL13553685 0.51 6/20
SCHEMBL13553594 SCHEMBL13553594 0.81 5/20
SCHEMBL1680968 SCHEMBL1680968 0.77 5/20
SCHEMBL13553590 SCHEMBL13553590 0.75 5/20
SCHEMBL13553475 SCHEMBL13553475 0.75 5/20
SCHEMBL13553508 SCHEMBL13553508 0.73 5/20
SCHEMBL13553774 SCHEMBL13553774 0.73 5/20
SCHEMBL12807686 SCHEMBL12807686 0.68 5/20
SCHEMBL13553775 SCHEMBL13553775 0.65 5/20
SCHEMBL13553779 SCHEMBL13553779 0.63 5/20
SCHEMBL13553509 SCHEMBL13553509 0.62 5/20
SCHEMBL13553476 SCHEMBL13553476 0.60 5/20
SCHEMBL13553787 SCHEMBL13553787 0.59 5/20

Clinical trials — most relevant to PAK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Safety and Feasibility of Metformin for Sepsis Induced AKI PHASE2COMPLETED
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) PHASE2WITHDRAWN
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PAK2 binder may also engage these)

ProteinNameSimilarity
Q7YQL3 — 1.000 Q7YQL3 →
Q7YQL4 — 1.000 Q7YQL4 →
PAK1 Serine/threonine-protein kinase PAK 1 1.000 landscape →
Q8CIN4 — 1.000 Q8CIN4 →
Q62829 — 1.000 Q62829 →
Q29502 — 1.000 Q29502 →
Q8AXB4 — 1.000 Q8AXB4 →
PAK3 Serine/threonine-protein kinase PAK 3 1.000 landscape →
P35465 — 0.999 P35465 →
Q64303 — 0.999 Q64303 →
Q08E52 — 0.998 Q08E52 →
O88643 — 0.997 O88643 →
Q9NB31 — 0.997 Q9NB31 →
Q17850 — 0.995 Q17850 →
O61125 — 0.995 O61125 →
Q99JT2 — 0.994 Q99JT2 →
A4K2Q5 — 0.993 A4K2Q5 →
A4K2P5 — 0.993 A4K2P5 →
A4K2T0 — 0.993 A4K2T0 →
A4K2W5 — 0.993 A4K2W5 →
Q9JI11 — 0.993 Q9JI11 →
Q5ZJK4 — 0.992 Q5ZJK4 →
Q7SY49 — 0.992 Q7SY49 →
Q9HFW2 — 0.991 Q9HFW2 →
O08875 — 0.991 O08875 →
Q2VWQ3 — 0.991 Q2VWQ3 →
Q61036 — 0.990 Q61036 →
B0LT89 — 0.990 B0LT89 →
Q9JLM8 — 0.990 Q9JLM8 →
Q6P3Q4 — 0.990 Q6P3Q4 →